The S&P/ASX 200 Index (ASX: XJO) has rebounded early this week. Here are four ASX 200 shares that I think can help drive the index higher over the next 12 months.
Image source: Getty Images
A2 Milk Company Ltd (ASX: A2M)
A2 Milk shares have crashed 26% since early April after the company released a trading, supply chain, and outlook update stating that it was experiencing significant supply chain disruptions that are expected to affect its FY26 performance. The ASX 200 company said it was facing temporary product availability issues in China, driven by strong demand, freight disruptions, production constraints, and longer product release and customs clearance times. As a result, the company downgraded its FY26 guidance, and it has sent the share price tumbling. Brokers are still bullish on the ASX 200 company's shares, though. Market Index data shows they rate the stock a buy and tip a 55% upside to $9.18 at the time of writing.
Vault Minerals Ltd (ASX: VAU)
Vault Minerals shares shed nearly 40% of their value amid a broad-based sell-off of ASX gold stocks following the escalation of conflict between the US and Iran and resulting global economic uncertainty. It looks like investors were also using the opportunity to take gains off the table after a strong price rally in late 2025. The ASX 200 gold company's shares have since recovered some ground, but sentiment has still been sluggish over the past month. Brokers are very optimistic about the outlook for the gold miner, though. They rate the ASX 200 shares as a strong buy and tip a potential 59% upside to $7.06.
Pro Medicus Ltd (ASX: PME)
Pro Medicus shares are climbing higher this week. The uptick is great news for investors after it suffered a brutal 53% sell-off over the past 12 months. On Monday, the healthcare imaging software company announced a new contract win. It said its US subsidiary, Visage Imaging, has signed a 7-year, $90 million contract with Beth Israel Lahey Health. The company's US subsidiary also won two $40 million five-year contract renewals back in early March. It looks like we'll see plenty more out of the company over the next 12 months, too. TradingView data shows analysts rate the ASX 200 shares as a strong buy and tip an average 47% upside to $191.90, at the time of writing.
Resmed Inc (ASX: RMD)
Resmed shares have rebounded from a two-year low recorded in mid-May. Again, as an ASX healthcare share, the company has faced significant headwinds in late 2025 and early 2026. Most significantly, Resmed shares were swept up in the general sector-wide sell-off. Its latest third-quarter earnings update also came in softer than expected, which didn't help lessen declining sentiment. But it looks like the ASX 200 shares are now widely considered oversold and below fair value. Broker consensus is for a strong buy rating. And they tip the shares to climb 51% higher to $43.38 over the next 12 months, at the time of writing.
